Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen

Inclusion Criteria: * Informed consent, signed by the subject. * Clinical History of moderate to severe rhinitis/rhinoconjunctivitis lasting for at least 2 consecutive years, with or without episodic asthma, caused by allergy to grass pollen. * Patient of both gender aged from 18 up to 55 * Symptoms that coincide with allergy to grass pollen * Sensitivity to grass pollen, diagnosed through a positive skin reaction to Phleum pratense: Positive prick test and /or Specific IgE to P.pratense \>0,7KU/L Patients included must be mono-sensitised or, in the case of poly-sensitisation, sensitivity to p.pratense pollen should be considered as the only relevant aspect of their condition from the clinical standpoint. * Patients who are able to comply with the dose regime Exclusion Criteria: * Patient with mild Rhinitis/rhinoconjunctivitis * Relevant sensitivity to another perennial allergen * Use of immunotherapy during the last four years * Treatment with B. Blocking agents * Patient suffering from some pathology in which adrenalin was contraindicated * Subject suffers from a serious medical condition, which would interference the treatment and follow up of the subject in the study * Subject suffers from autoimmune disease(thyroiditis, lupus, etc.) * Conditions in which the patient can not offer full co-operation and significant psychiatric disorders. * Intolerance to aspirin * Pregnant women or with pregnancy risk and breast-feeding